Paloma Partners’s Viridian Therapeutics VRDN Stock Holding History

Paloma Partners’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-7,780	Closed	-$239K	–	2308
2019 Q2	$239K	Buy	+7,780	New	+$312K	﹤0.01%	1429

Other funds holding VRDN

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paloma Partners's VRDN Position: Q3 2019 in Review

Paloma Partners sold out of Viridian Therapeutics (VRDN) in Q3 2019, closing a stake of 7,780 shares — an estimated $239K sold.

Paloma Partners first reported a position in VRDN in Q2 2019 and held it in 1 quarter. The position peaked at $239K in Q2 2019. 33 funds tracked by Wall St. Rank hold VRDN as of Q3 2019.

Paloma Partners reported no remaining Viridian Therapeutics position as of Q3 2019 after selling out during the quarter.
Paloma Partners sold 7,780 Viridian Therapeutics shares in Q3 2019, an estimated $239K.
Paloma Partners first reported a position in Viridian Therapeutics in Q2 2019 and held it in 1 quarter.
Paloma Partners's Viridian Therapeutics position peaked at $239K in Q2 2019.
33 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.